Tesamorelin
Tesamorelin — Growth Hormone Releasing Hormone (GHRH) analog
A growth hormone releasing hormone analog with a narrow FDA-approved indication for visceral fat reduction in a specific patient population.
What Is Tesamorelin?
Why Is Tesamorelin Being Studied?
- Visceral fat reduction (within the approved indication)
- Growth hormone pathway stimulation
- Body composition research more broadly (off-label)
- Metabolic marker changes in clinical trial populations
How Does It Work?
Tesamorelin binds to GHRH receptors on the pituitary gland, stimulating growth hormone release through the body's natural signaling pathway. In clinical trials within its approved population, this growth hormone stimulation was associated with measurable reductions in visceral adipose tissue.
Tesamorelin
Pituitary GHRH receptor activation
Growth hormone release & downstream lipolytic signaling
Visceral fat reduction demonstrated in its approved clinical population
What Does The Evidence Say?
Human Research
Randomized controlled clinical trials supported FDA approval of tesamorelin (Egrifta) specifically for reducing excess visceral fat in HIV-infected patients with lipodystrophy. Evidence for broader, off-label body composition use outside this population is more limited.
Preclinical Research
Preclinical pharmacology research characterized GHRH receptor activity and growth hormone-releasing effects prior to and alongside human trials.
What We Don't Know Yet
How tesamorelin performs for general body composition goals outside its specific approved population has not been established through the same rigorous trial process that supported its approved indication.
Areas of Research
Metabolic Health
The approved indication centers on visceral fat reduction, a key metabolic health marker.
Muscle & Body Composition
Growth hormone pathway stimulation has broader research interest in body composition contexts.
Why Might Someone Discuss This With Their Provider?
Someone evaluating visceral fat or growth hormone pathway therapies may want to understand both the approved, narrow indication and the broader off-label research context for tesamorelin.
Whether a therapy is appropriate depends on individual health history, medications, goals and clinician evaluation.
Important Considerations
Tesamorelin (brand name Egrifta) is FDA-approved specifically for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Use outside that approved indication and population is considered off-label.
This compound's one clearly approved use is narrow and population-specific. Off-label use should be discussed as an individualized decision with a licensed healthcare provider, who can review appropriateness, risks, and monitoring needs.
Related Peptides
Sermorelin
A growth hormone releasing hormone fragment with a longer research and clinical history than many newer growth hormone secretagogues.
CJC-1295 / Ipamorelin
A two-peptide combination studied for its potential role in supporting the body's natural growth hormone release pathways.
Research & References
No references have been added for this entry yet. This library is updated on an ongoing basis.
The Peptide User Guide is provided for educational purposes and is not intended to diagnose, treat, cure, prevent, or provide individualized medical advice. Research surrounding many peptides and investigational therapies continues to evolve, and the strength of evidence varies significantly between compounds and applications. Treatment decisions should be made in consultation with a qualified healthcare professional.